Background It frequently takes more than 2 weeks for drug treatments for cryptococcal
meningitis to sterilise cerebrospinal fluid (CSF). In-vitro and animal studies lend support to …

Background Combination antifungal therapy (amphotericin B deoxycholate and flucytosine)
is the recommended treatment for cryptococcal meningitis but has not been shown to reduce …

Background Cryptococcal meningitis accounts for more than 100,000 human
immunodeficiency virus (HIV)–related deaths per year. We tested two treatment strategies …

Background. Cryptococcosis is a life-threatening infection among patients with human
immunodeficientcy virus (HIV) infection. Therapeutic options for the treatment of central …

Abstract (See the Editorial Commentary by Bennett, on pages 129–30.) Background. HIV-
associated cryptococcal meningitis is associated with an estimated 600 000 deaths …

Background. The standard therapy for human immunodeficiency virus (HIV)–associated
cryptococcal meningitis of amphotericin B (AmB; 0.7 mg/kg per day) plus flucytosine …

Background. Cryptococcal meningitis is a major cause of human immunodeficiency virus
(HIV)–associated morbidity and mortality in Africa. Improved oral treatment regimens are …

In a prospective observational study of 54 patients with human immunodeficiency virus–
associated cryptococcal meningitis, the early fungicidal activity of amphotericin B (1 …

Background Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight
per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome …

Background: Interferon-gamma (IFNγ) is of key importance in the immune response to
Cryptococcus neoformans. Mortality related to cryptococcal meningitis remains high, and …